Surprise FDA Red Flags May Jeopardize Blockbuster Drugs

Regeneron is today's big loser in the biotech space because of a new set of FDA concerns over its PCSK9 drug. The FDA is now concerned that this class of drugs, aimed at lowering "bad" cholesterol in the bloodstream, could have a number of neurocognitive adverse effects in patients. Amgen has a drug in this class, as well, that is considered a critical product for the company; it also saw shares fall today.

In this video from Friday's Market Checkup, Motley Fool health-care analyst David Williamson discusses this potentially multi-billion dollar blockbuster drug class, and how likely these FDA concerns are to derail these drugs.

Regeneron was today's loser. Here's a stock we think is a long-term winner.
Opportunities to get wealthy from a single investment don't come around often, but they do exist, and our chief technology officer believes he's found one. In this free report, Jeremy Phillips shares the single company that he believes could transform not only your portfolio, but your entire life. To learn the identity of this stock for free and see why Jeremy is putting more than $100,000 of his own money into it, all you have to do is click here now.

The article Surprise FDA Red Flags May Jeopardize Blockbuster Drugs originally appeared on Fool.com.

David Williamson has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2014 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.